+39 339 659 6105 info@hepbcppa.org

Menu
Finance & Transparency

Sponsorship 2009-2016 Hepatitis B&C Public Policy Association asbl


SPONSOR AMOUNT EUROSACTIVITIES
2009/2010
Gilead Sciences Europe Ltd 428,987.00 Set-up & 2010 Summit
Janssen Pharmaceuticals NV 140,000.00 Set-up & 2010 Summit
GlaxoSmithKline Biologicals SA 30,000.00 2010 Summit
Bristol Myers Squibb EMEA SARL 50,000.00 2010 Summit
Schering-Plough 175,000.00 2010 Summit
2011/2012
Gilead Sciences Europe Ltd 250,000.00 Unrestricted & 2012 Summit
Janssen Pharmaceuticals NV 75,000.00 Educational grant
Bristol Myers Squibb EMEA SARL 35,000.00 2011/2012activities & 2012 summit
Gilead Sciences Hellas M.EPE 15,000.00 2011 Call to action
2013/2014
Bristol Myers Squibb EMEA SARL 45,000.00 2013 Activities & Summit 2014
Merck Sharp and Dohme 20,000.00 2012 Conference
Gilead Sciences Europe LTD 203,000.00 2013 Activities & Summit 2014
Gilead Sciences Hellas M.EPE 18,000.00 Summit 2014
Abbvie Pharma S.A. Greece 70,000.00 Summit 2014 & 2014 activities
Bristol Myers Squibb EMEA SARL 45,000.00 2014 Summit & activities
2015/2016
Gilead Sciences Europe Ltd 180,000.00 Core funding 2015 & 2016 EU HCV Policy Summit
Abbvie Pharmaceuticals France 130,000.00 2016 EU HCV Policy Summit
Bristol Myers Squibb EMEA SARL 45,000.00 EU HCV Policy Summit 2016 & the Innovative Finance Initiative to Tackle HCV in Europe
Bristol Myers Squibb USA 17,774.00 EU HCV Policy Summit 2016 & related activities
Abbvie Pharmaceuticals France 50, 000.00 Elimination days in Brussels dedicated to the elimination of HCV in three EU countries
Abbvie Pharma S.A. Greece 11,000.00 National roundtable on the Elimination Manifesto, Athens, September 2016
Gilead Sciences Europe Ltd 348,000.00 Core funding 2016 & the Innovative Finance Initiative to Tackle HCV in Europe
Merck Sharp and Dohme 30, 000.00 EU HCV Policy Summit 2016